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A B S T R A C T
Pharmacies hold great potential to contribute meaningfully to tuberculosis (TB) control eﬀorts, given their ac-
cessibility and extensive utilisation by communities in many high burden countries. Despite this promise, the
quality of care provided by pharmacies in these settings for a range of conditions has historically been poor. This
paper sets out to conceptualise the key issues surrounding quality of TB care in the low- and middle-income
country pharmacy setting; examine the empirical evidence on quality of care; and review the interventions
employed to improve this. A number of quality challenges are apparent in relation to anti-TB medicine avail-
ability, pharmacopeial quality of anti-TB medicines stocked, pharmacy workers’ knowledge, and management of
patients both prior to and following diagnosis. Poor management practices include inadequate questioning of
symptomatic patients, lack of referral for testing, over-the-counter sale of anti-TB medication as well as un-
necessary and harmful medicines (e.g., antibiotics and steroids), and insuﬃcient counselling. Interventions to
improve pharmacy practice in relation to TB control have all fallen under the umbrella of public-private mix
(PPM) initiatives, whereby pharmacies are engaged into national TB programmes to improve case detection.
These interventions all involved training of pharmacists to refer symptomatic patients for testing and have
enjoyed reasonable success, although achieving scale remains a challenge. Future interventions would do well to
expand their focus beyond case detection to also improve counselling of patients and inappropriate medicine
sales. The lack of pharmacy-speciﬁc global guidelines and the regulatory environment were identiﬁed as key
areas for future attention.
1. Introduction
In low- and middle-income countries (LMICs), the core function of
community pharmacists has long been narrowly focused on dispensing
and retailing. In the context of tuberculosis (TB) care, this limits the
role of pharmacies to ﬁlling prescriptions for anti-TB medication.
However, their potential importance in the ﬁght against TB could be so
much greater, given their accessibility and extensive utilisation by
communities. First, pharmacists can play a key role in diagnosis.
Research from many high burden countries reports that patients ex-
periencing the non-speciﬁc symptoms of TB (typically a prolonged
cough) often seek care, in the ﬁrst instance, at a private pharmacy
[1–4]. Poor quality management at this stage can lead to delayed di-
agnosis and negatively aﬀect both case detection and disease control.
Capitalising on diagnostic opportunities in pharmacy settings is perti-
nent given that 3.6 million (36%) of TB cases globally are deemed to be
‘missing’ [5] and the top three countries accounting for this global gap
(India, Nigeria and Indonesia) all have large community pharmacy
sectors. For illustration, Indonesia has 24,716 pharmacies which ac-
count for 52% of initial care seeking, yet currently notify not a single
case [6]. Secondly, pharmacists have a key role in managing TB patients
following diagnosis; this involves ensuring that anti-TB medications are
dispensed (against prescriptions) alongside appropriate advice to en-
sure safe and eﬀective use, and encourage adherence. Finally, given
their prevalence in many high burden settings, pharmacies could take
on a role in the provision of directly observed therapy (DOTS), a cor-
nerstone of the Stop TB Strategy [7].
The importance of pharmacies for TB control eﬀorts has been re-
cognised at the global level and this falls within a wider movement to
encourage the engagement of private providers within national TB
programmes (public private mix- PPM) [8]. A joint statement from the
International Pharmaceutical Federation (FIP) and the World Health
Organization (WHO) in 2011 urged ‘national TB programmes and na-
tional pharmacy associations to develop and implement plans for en-
gaging pharmacists in the ﬁght against TB’ [9]. Konduri and colleagues
have shown, however, that this recommendation has not been widely
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translated into practice, and pharmacy involvement remains nominal
[10].
Despite the promise that LMIC pharmacies hold for global TB con-
trol eﬀorts, the quality of care they provide across a range of health
conditions has, historically, been plagued by shortcomings. Across
Africa, Asia and Latin America research has consistently highlighted
frequent absence of trained pharmacists or other qualiﬁed personnel;
poor practices in ﬁlling prescriptions; inadequate management of pa-
tients including insuﬃcient history taking, lack of appropriate medical
referral, sale of medicines that are clinically inappropriate, and limited
provision of advice; and endemic regulatory infringement such as sale
of prescription only medicines (POMs) without a prescription [11,12].
This paper explores the potential of pharmacies to address these
well-documented quality shortfalls in relation to TB care. It forms part
of a series of papers examining various aspects of quality in relation to
TB control [13]. We deﬁne ‘pharmacy’ in a broad sense - that is any
outlet or individual who is recognised by the regulatory system to sell
medicines. This includes licensed pharmacies, whether or not a quali-
ﬁed pharmacist is actually present, and also in some countries au-
thorised drug shops where non-pharmacist personnel are allowed to
operate a basic pharmacy, for example Accredited Drug Dispensing
Outlets (ADDOs) in Tanzania or Patent Medicine Vendors (PMVs) in
Nigeria. We begin by conceptualising the key issues surrounding quality
of TB care in the pharmacy setting. Secondly, we examine the methods
used for studying quality of care in pharmacies. Thirdly, we provide an
overview of the empirical evidence on the quality of TB care provided
by pharmacies in LMICs, and the interventions employed to improve
this. Finally, we reﬂect on the future of pharmacy involvement in TB
control eﬀorts.
2. What quality of care do we expect from pharmacies?
Quality can be considered to have three broad dimensions: structure
or foundations, processes and outcomes [23,24]. We focus mainly on
the process of care, given that this element is directly in the hands of
pharmacy workers. While structural quality has been cited as a poor
proxy for the process of diagnosis and treatment [25–27], we also
consider some essential structural elements (workforce and tools)
(Table 1). Our focus is primarily on these technical aspects of care
provision, rather than user experience.
Whilst the WHO's ‘International Standards for TB Care’ provides
general guidance for all providers on the diagnosis and treatment of TB
internationally, there is no single global document available that covers
the pharmacy's role in TB care holistically. It can thus be diﬃcult to
benchmark the quality of current practices. However, there are some
national pharmacy-speciﬁc TB guidelines. For example, the Revised
National Tuberculosis Control Programme (RNTCP), India, released a
‘training module for community pharmacists’ in collaboration with the
Indian Pharmacy Association which sets out the role and responsi-
bilities of the pharmacist in TB care [28]. These guidelines are explicit
in terms of the pharmacist's role under headings such as ‘case detection
and referral of TB suspects’ and ‘rational use of antibiotics and anti-TB
drugs’. Further, there are sections of global level documents that are
relevant e.g., WHO's ‘Practical Pharmacy For Developing Countries’
issue on TB and FIP/WHO's joint statement on the role of pharmacists in
TB care [9,29]. Drawing on these, Box 1 outlines what pharmacy
workers arguably should be doing in relation to diagnosis, dispensing,
and counselling.
Box 1
Expectations of pharmacy workers in TB management
Diagnosis
The management of a TB patient is outside the realm of a
pharmacist's expertise and, as such, suspected cases should be
referred for testing. Some national programmes (or pilot projects)
encourage pharmacies to actively triage and refer patients with a
cough of duration two weeks or longer for sputum testing to a
nearby designated microscopy centre. First or second line anti-TB
medicines, along with any antibiotics (especially ﬂuor-
oquinolones) should not be sold without a prescription. Steroids
can mask TB symptoms leading to a delayed diagnosis and thus
should not be sold over-the-counter (OTC) [30].
Dispensing
One area where the pharmacist's role is clear-cut is in dis-
pensing of anti-TB medicines. These medicines should be dis-
pensed in accordance with the prescription, in the correct dosage,
for the speciﬁed duration. FIP/WHO specify that pharmacists
should ‘ensure that quality-assured medicines are procured and
supplied and that ﬁxed-dose combinations recommended by
WHO are used. Furthermore, dispensing anti-TB medicines that
have not been certiﬁed as safe and eﬀective and sale of in-
appropriate combinations should be stopped’ [9]. Where phar-
macists detect potential errors on prescriptions for TB medicines,
the prescribing doctor should be contacted.
Counselling
Pharmacist counselling is of particular importance for anti-TB
medicines. Adherence is challenging given the long duration of
the course, high number of pills, and potential side eﬀects (some
of which may be alarming e.g., orange or red urine and tears).
Provision of information outlining what to expect when under-
going such treatment is essential to empower patients and help
them to achieve treatment success. Essential medicine informa-
tion that TB patients need to be made aware of includes the im-
portance of continuing treatment even after alleviation of symp-
toms; the need to check for interactions before taking any other
medication, given the enzyme-inducing eﬀects of rifampicin
which can alter the way other medicines work (e.g., it reduces the
eﬀectiveness of oral contraceptives); the need to limit alcohol use;
the possibility that they may experience a range of side eﬀects;
and that they must report symptoms that may indicate toxicity
such as changes in vision or yellow skin [29].
The role of registered drug shops and characterisations of ‘correct
TB management’ is less well deﬁned, and arguably more limited. For
example, in Tanzania, ADDOs are legally prohibited from stocking ﬁrst-
line anti-TB medication [31]. Such outlets still have an important role
to play in terms of case detection given the treatment seeking behaviour
of patients with cough and fever, but interestingly there has been re-
luctance amongst other health professionals to recognise referrals from
such providers (ibid).
For this paper, we reviewed the literature to examine the methods
used for studying quality of care in pharmacies; the quality of TB care
Table 1
Key aspects of TB care quality in pharmacies.
Structural aspects/foundations of quality Processes of care
• Knowledge of pharmacy staﬀ regarding TB care for symptomatic and
diagnosed patients.
• Availability of anti-TB medicines.• Pharmacopeial quality of anti-TB medicines.
• Appropriate referral of symptomatic, undiagnosed TB patients presenting at the
pharmacy.
• Ensuring that symptomatic, undiagnosed TB patients do not receive harmful medicines,
such as antibiotics.
• Accuracy of dispensing of prescriptions for anti-TB medicines.• Quality of counselling to accompany dispensing of anti-TB medicines.
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provided by pharmacies; and interventions to improve such care. In the
three sections that follow we present our ﬁndings. The intention of this
overview was not to conduct an exhaustive, systematic search of the
literature; but rather, to identify key themes in the literature and pro-
vide a narrative review. Included papers were identiﬁed through the
reference lists of prior, relevant reviews (including their appendices)
[6,10–12,14–18]. We included papers concerned with any of the as-
pects of quality laid out in Table 1, from a quantitative or qualitative
perspective. Reference lists of included papers were then also screened
for relevant material. We acknowledge that this approach has its lim-
itations, and that grey literature (including TB program reports that are
rarely publicly available) has not been included.
3. Methods for studying quality of TB care from pharmacies
Commonly used tools for measuring the quality of pharmacy care
encompass surveys and medical vignettes, abstraction of information
from medical records, (covert) standardised patients, exit interviews
with patients, and direct observation of the patient-provider interac-
tion. Some of these methods have been employed to measure various
aspects of TB care quality in LMIC pharmacy settings.
Questionnaires have been used to measure structural aspects of care
quality including staﬀ knowledge and availability and stock manage-
ment of TB medicines (e.g., [32–34]). Questionnaires have also been
used to gather information on reported case management practices
(ibid). Results from the latter should be interpreted with caution,
however, because such reports can be subject to social desirability bias.
Studies looking at a range of conditions have revealed vast dis-
crepancies between knowledge or stated practice for hypothetical sce-
narios (vignettes) and actual practice for sale of medicines, referral for
medical attention, history taking and provision of advice (e.g.,
[35,36–38]). This phenomenon whereby providers do not necessarily
do what they know they should do has been termed the ‘know-do’ gap
[39].
Three studies have used standardised patients to assess TB care,
whereby people from the local community were trained to pretend to be
real patients seeking care at pharmacies. They presented various pre-
speciﬁed scenarios of TB and subsequently recorded the details of the
encounter [30,40,41]. This method confers several advantages over
alternative quality measures and has been described as the ‘gold stan-
dard’ for measuring quality [26]. It is free from the aforementioned
social desirability bias associated with vignettes and the Hawthorne
eﬀect that accompanies direct observation. Further, it avoids issues of
confounding that can arise due to patient and case mix [42]. In the
pharmacy context, it is unsurprising that there are no studies that report
using exit interviews or observation of encounters to measure TB care
quality. This is because TB patients are unlikely to make up a large
proportion of conditions seen at the pharmacy on a daily basis. It would
therefore be logistically diﬃcult and time consuming to collect data on
this condition through such means. Pharmacies tend not to keep records
of encounters with patients (asides from for the sale of restricted POMs
e.g., opioids) which rules out the use of retrospective record abstrac-
tion.
Anthropologists have used ethnographic methods to better under-
stand and describe the pharmacist-client interaction [43,44], though no
such studies have reported on TB management, again likely due to its
relatively uncommon presentation. However, there are examples of
ethnographic work based in the community seeking to understand
pharmaceutical consumption that have provided insights into care
seeking and the role played by community pharmacy in TB manage-
ment (e.g., [45]).
4. Empirical evidence on quality of TB care from pharmacies in
LMICs
4.1. TB medicine availability
Empirical evidence on availability of anti-TB medicines from private
pharmacies in LMICs is scant. It shows that availability across settings is
variable, with gaps in stocking ﬁrst-line anti-TB medicines ranging from
a third to three quarters. A study in Cochabamba city, Bolivia, reported
that 99 out of 100 sampled pharmacies were unable to completely ﬁll a
prescription for one week's supply of rifampicin 300 mg, isoniazid
150 mg, ethambutol 400 mg and pyrazinamide 500 mg [46]. Only 25%
stocked at least one of the medicines. The most commonly stocked was
rifampicin (23%) which was said to be used for indications other than
TB. In Hanoi, Vietnam, 49% of 128 pharmacy workers said they stocked
at least two ﬁrst-line anti-TB medicines [41]. Surveys from Latipur,
Nepal [47] and Ho Chi Minh City (HCMC), Vietnam [32], have revealed
that 74% and 60% of pharmacies reported stocking anti-TB medication
respectively. In Cambodia, drug availability data collected from 66
private pharmacies in 14 provinces showed that the most frequently
available anti-TB medicines were pyrazinamide (71%), rifampicin
(70%), streptomycin (62%), and ethambutol (56%) [34].
4.2. Anti-TB medicine quality
Several studies have reported on the prevalence of substandard and
falsiﬁed anti-TB drugs in LMICs (e.g., [48,49]). Perhaps the largest one
of its kind assessed the quality of isoniazid and rifampicin procured
from private pharmacies across 19 cities in Angola, Brazil, China, DRC,
Egypt, Ethiopia, Ghana, Rwanda, India, Kenya, Nigeria, Russia, Thai-
land, Turkey, Uganda, Tanzania, and Zambia. The authors report that of
the 713 treatment packs procured, 9.1% failed basic quality testing for
required levels of active pharmaceutical ingredient or disintegration
[50]. Failure rates were 17%, 10% and 4% in Africa, India, and other
middle-income countries respectively. These results are similar to an
earlier multi-country study which tested isoniazid, rifampicin, and
ﬁxed-dose combinations (FDCs) from selected TB programmes in Co-
lombia, Estonia, India, Latvia, Russia and Vietnam. Overall 10% of
samples (4/40) were found to contain <85% of the stated content [51].
More FDCs were found to be substandard than single drug samples.
Table 2
Examples of TB case presentations and management of TB in standardised patient studies.
Study Case presentation Management
Referred Sold an antibiotic
Miller and Goodman 2017, India [40] ‘I have had cough and some fever for 3–4 weeks. We have had a relative staying with us who has TB. Can
you suggest something?’
46% 16%
Satyanarayana et al. 2016 (case 1),
India [30]
‘I am having cough for nearly a month now and also have fever.' Whilst showing a positive sputum report
to the chemist, the patient continues, 'I went to the government dispensary and they asked me to get my
sputum tested. I have this report. Can you please give me some medicine?'
16% 37%
Satyanarayana et al. 2016 (case 2),
India [30]
`I have cough and fever that is not getting better. Please give me some medicine.' 67% 16%
Vu et al. 2012, Vietnam [41] SP claimed to be suﬀering from cough and fever for 4 weeks. No improvement had occurred after two 10-
day courses of antibiotics (amoxicillin followed by spiramycin). SP had been in contact with a TB patient.
Anti-TB drugs were requested. (The paper does not provide the verbatim script).
46% 41%
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Worryingly, a study from India reported that TB FDCs purchased from
pharmacies all failed accelerated stability testing at 3 months having
passed the initial ingredient content assays (range 90–100%) [52]. This
indicates that under common Indian climatic conditions, TB medicines
being purchased may be unstable.
4.3. Knowledge of TB amongst pharmacy providers
Across a range of studies knowledge was variable, with some in-
dicators revealing poor results. Several studies have collected data on
knowledge pertaining to the activities of the national control pro-
gramme. For example, a study of 300 randomly selected pharmacies in
Tamil Nadu, India, reported that all pharmacists were aware of the
availability of free anti-TB medicines from government facilities; but
fewer (15%) had heard of the national TB programme and only 5%
knew about the DOTS strategy [53]. Figures diﬀered in other settings
with two thirds of pharmacies in the Vietnamese capital, Ho Chi Minh
City (HCMC), stating they were aware of the national programme; in
another large Vietnamese city, Hanoi, 27% of study pharmacies were
aware that the national programme provided free treatment; and in
Nigeria, a study of PMVs revealed that over half had never heard of
DOTS [32,33]. Studies have also sought to measure knowledge of TB
management and symptoms; results have tended to be disappointing. In
Nepal, 14% of study pharmacy workers believed TB treatment duration
was less than four months and only 1/50 knew the correct regimen
[54]; in Vietnam, when presented with a case description of a patient
with cough for 4 weeks and fever, only 18% of participants in HCMC
and 42% in Hanoi mentioned TB as a potential diagnosis [32,41]; in
Nigeria around half of PMVs did not know the cause of TB [33].
4.4. Reported management practices for TB patients
We are only aware of a handful studies that have explored self-re-
ported management practices for TB patients among pharmacy provi-
ders. A high proportion (88%) of pharmacies in HCMC said that a pa-
tient with pulmonary TB required medical attention to ascertain a
diagnosis [32]. Over half of these same participants reported selling
anti-TB drugs sometimes or often, and of those, 24% reported selling
such drugs without a prescription. Of 388 PMV study participants in
Nigeria, fewer than 10% reported sending patients with prolonged
cough or suspected TB for a laboratory test, and just over half (57%)
reported referring TB cases to a higher facility [33].
4.5. Actual management practices for TB patients
Standardised patients have been used to show how TB suspects are
managed in practice, in both India [30,40] and Vietnam [41]. These
studies have used varying case presentations (Table 1). In Vietnam, we
are not aware of any speciﬁc guidelines for the management of TB
patients by pharmacists. As per Box 1, we would expect patients pre-
senting with TB symptoms to be referred. The study reports that fewer
than half of 126 pharmacies [46] referred the SP for diagnosis; only 9%
referred to a designated TB facility; 53% sold medicines to the SP; and
41% sold an antibiotic [41].
The SP studies in India benchmarked the management of these
patients against the recommendations of the RNTCP and the Indian
Pharmaceutical Association [28]. ‘Correct’ management in both studies
was deﬁned as referral to a TB clinic/DOTS centre or heath care pro-
vider without dispensing any antibiotics or steroids (which were
deemed to be harmful). Depending on the case presentation, correct
management ranged from 13% to 62% and dispensing of an antibiotic
from 16% to 37% [55]. In a pooled analysis of results across the three
Indian cities from both studies, the authors reported that behaviour
improved markedly as the certainty of the diagnosis was more apparent
(ibid). For example, those presenting with cough and fever, for which
there are several diﬀerential diagnoses, were only managed correctly by
13% of providers. This increased to 45% when the SP mentioned con-
tact with a relative with a TB diagnosis; and to 62% when they pre-
sented a conﬁrmed positive sputum test. Miller and Goodman [40] also
reported on history taking and advice provision. They found that less
than a quarter of providers asked the SP any questions to determine a
diagnosis (a necessity given that the symptoms of cough and fever are
non-speciﬁc); fewer than 2% advised that TB treatment was available
free of charge from government facilities. Encouragingly, none of the
providers in either India or Vietnam sold ﬁrst line anti-TB drugs to the
SPs.
5. Interventions to improve TB care from pharmacies in LMICs
In its 2006 document ‘Engaging all health care providers in TB
control’ the WHO outlined the importance of engaging pharmacists and
drug outlets in national TB control eﬀorts and provided guidance on
how to implement public-private mix (PPM) approaches [8]. Konduri
and colleagues conducted a comprehensive review of ‘engagement of
the private pharmaceutical sector for TB control’ and identiﬁed 52 in-
terventions involving retail drug outlets [10]. However, the majority of
these interventions were identiﬁed from conference abstracts, which
provide limited detail. 15 provided data on the number or percentage of
referrals of presumptive TB cases or resulting positive cases. These in-
terventions (carried out between 2003 and 2014) involved between 60
and 683 retail drug outlets; referrals ranged between 0.25 and 9 per
retail outlet; of referrals, the percentage screened ranged from 27% and
91%; and the number of smear positive cases ranged from 3 to 395
(ibid). This review concluded that, to date, eﬀorts to engage pharmacies
have been limited. In this section, we focus on seven interventions (for
which full research papers are available) that have sought to address at
least one aspect of quality of care laid out in Table 1 (see Table 3 for
details). All were carried out in conjunction with the national TB pro-
gramme of the study country and are classiﬁed as PPM projects
[56–63].
All interventions aimed to improve the management of TB patients
by participating pharmacies through training of pharmacy staﬀ to
screen patients and appropriately refer TB suspects, with the ultimate
aim of improving case detection. Most training focussed on symptoms
of TB and identifying patients to refer for testing. A minority of inter-
ventions also focussed on rational medicine use and antibiotic stew-
ardship [58,59]. One study mentioned that the training covered coun-
selling for patients prescribed anti-TB medication [59]. In addition to
improving case detection eﬀorts, one intervention additionally sought
to stop pharmacies from selling anti-TB medicines [60]. Two inter-
ventions in India and Vietnam incorporated ﬁnancial incentives for
pharmacy referrals [58,63].
Most programmes had a relatively low engagement with around
30–40% of pharmacies actively participating in the referral process;
Daftary and colleagues [58] are the exception, reporting 81% active
participation in Patna, India. Workload, patient demand for OTC
medicines, doctor fees, programme paperwork, fear of losing patients to
other pharmacies (and hence the opportunity to sell medicines such as
antibiotics and cough suppressants), and concern that patients would
criticise the pharmacist were they to receive a negative TB diagnosis all
negatively aﬀected engagement [58,61]. Across the studies, of patients
referred by pharmacies, positive TB diagnoses ranged from 7 to 27% of
patients tested. In India, an intervention which added several compo-
nents to a broader PPM programme, reported a TB diagnosis rate that
was 25 times higher than the standard programme alone, indicating
that a multi-faceted approach including ﬁnancial incentives, regular
SMS reminders, and regular supervision and monitoring could have a
key role in maintaining high levels of pharmacy engagement [58]. One
study using SPs to assess the eﬀects of the intervention reported re-
ductions in both antibiotic and cold remedy sales, alongside improved
detection rates [62]. Finally, a lack of cost data is evident, with only one
study considering the cost-eﬀectiveness of its case ﬁnding eﬀorts.
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6. Discussion and future directions
In this paper we mapped out what is expected of pharmacies in
relation to quality TB care and then examined the evidence to shed light
on the degree to which this is occurring. The expectations of pharma-
cists included matters pertaining to accurate dispensing of medicines
but also encompassed wider issues such as case management. This is in
line with global thinking regarding the role of community pharmacists
which has seen a shift from solely retailing of products to taking on a
substantial public health role comprising promotion, prevention, and
disease management [19]. Mossialos and colleagues argue that no
country can boast the latter (ibid). In LMICs there is an increasing
Table 3
Interventions to improve management of TB in the pharmacy setting in LMICs.
Author Country and programme Details of intervention Key ﬁndings/outcomes
Bell et al. [56] Phnom Penh, Cambodia
National center for Tuberculosis and
Leprosy Control public/private mix TB
Referral Programme
- 170 private pharmacies.
- Clients with TB symptoms are referred by pharmacy
to public sector DOTS clinics.
- 3-day training for pharmacy staﬀ and visits to DOTS
clinics.
During previous 3 months:
- One third of the pharmacies reported referring one
or more clients.
- The 170 pharmacies referred a total of 125 clients.
- 96% stated they always referred all clients with TB
symptoms to DOTS clinics.
Colvin et al. [57] Kisarawe district, Tanzania
National Tuberculosis and Leprosy
Programme, PATH, and USAID.
- 15 pharmacists (and 15 traditional healers) received
2 days training.
- Pharmacies given referral slips and registers to track
referrals to DOTS, and directory of DOTS facilities.
- Between 2009 and 2011 smear-positive TB case
notiﬁcation increased from 28 to 47/100,000
- Pharmacies referred 434 people to diagnostic
facilities. 97% acted on the referral, and of these,
25% were diagnosed with TB.
- New TB case notiﬁcations (in the study district)
referred through the network ranged from 38% to
70%.
Gharhat et al.
[59]
Mumbai, India
Mumbai District Tuberculosis Control
Society, colleges of pharmacy,
professional associations of pharmacists
and physicians.
- 119 pharmacist
- 2 interactive workshops
- Advised to refer patients with suspected TB and to
counsel patients prescribed anti-TB medicines
- Anecdotally, participation in the workshops was
associated with a high degree of professional
satisfaction.
- No measurement of pharmacist performance post
training.
Lonnroth et al.
[61]; Quy,
et al. [63]
Ho Chi Minh City, Vietnam - 150 pharmacies trained according to NTP guidelines
- New referral and recording system.
- Clients with TB symptoms referred for sputum smear
microscopy at a District TB Unit.
- US $1 for each sputum-positive detected case
- 39% referred at least one client to a TB
- 310 TB suspects were referred during ﬁrst 9-month
monitoring (only 28% went for testing).
- An additional 63 patients were referred and tested
in 2nd follow-up.
- 7% of the 149 patients tested were sputum-positive
(accounting for 1.6% of cases detected in the
intervention (others resulted from GP and physician
referrals).
Mitchell et al.
[62]
Santo Domingo, Dominican Republic - Intervention aimed at pharmacies and local grocery
stores
- Components of intervention involved a 1 h
educational workshop and a motivational ‘detailing
visit’
- Participants were invited to sign a pledge and receive
a certiﬁcate of recognition.
- SPs (reporting a set of chronic TB symptoms) were
sent 3–6 weeks before the interventions began and
again 2–6 weeks afterwards.
- Pharmacies exposed to the intervention improved
by 2.12 points (score based on TB behaviours e.g.,
recognition of symptoms) on average compared
with an improvement of 0.9 in the comparison
group (p = =0.06)
- Half of intervention pharmacies referred SPs
directly to the national TB program vs. 18.2% of the
control group.
- After intervention attempts to sell a medicine
including antibiotics without a prescription (e.g.,
amoxicillin, cephalosporin, rifampicin) fell from
38% of pharmacies to none.
- At 6 months follow-up, 33% of pharmacies referred
70 TB suspects of which 7 cases (10%) resulted in a
smear positive diagnosis.
- At 2 year follow-up, detection of new smear positive
cases averaged 150 per quarter vs. 67 per quarter in
the pre-intervention period.
Daftary et al.
[58]
Patna, India
Intervention nested into Universal Access
to TB Care (a PPM programme between
Bihar state government and PPIA World
Health Partners).
- Broader PPM programme involved 554 pharmacies
in standardised TB management plus incentive of US
$0.75 for each completed referral.
- Intervention (105 pharmacies) had 5 additional
components: interactive training workshops; referral
of TB suspects for chest radiograph and doctor
consultation; ﬁnancial incentives for referral
completion, chest radiograph and positive TB
diagnosis ($0.75, $1.50, and $3 respectively), text
message reminders and ﬁeld support.
- 81% of pharmacy providers actively participated
in the pilot vs. 16% in original PPM programme.
- Rate of registration of patients with TB symptoms
and positive TB diagnoses were 62 and 25 times
higher respectively in the intervention group.
- Microbiological testing and test conﬁrmation was
also signiﬁcantly higher in the intervention group.
- 240 additional cases were attributed to the
intervention with a cost per case notiﬁed of US
$100.
Lambert et al.
[60]
Cochabamba, Bolivia
NTP and local pharmacists association
(ASPROFAR)
- A two stage intervention
- Phase 1: 170 pharmacists attended a general meeting
and local pharmacists association issued a
recommendation to members to stop selling anti-TB
medicines and refer clients seeking to public services.
- Phase 2: 70 pharmacies referred clients with chronic
cough to NTP (via referral slip).
- After phase 1, the proportion of pharmacies
selling TB drugs decreased (rifampicin:
23–11.5%; isoniazid:
16–3.1%; P < 0.001) and the proportion of pharmacies
referring to the NTP clients seeking TB drugs increased
(22–58%; P < 0.0001).
- In phase two, 38% referred a total of 41 clients for
screening in the NTP; 11 of 41 (27%) were screened
and of these, 3 (27%), were diagnosed with smear-
positive TB.
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acknowledgement, and advocacy from both national and global phar-
macy bodies that pharmacists in these settings could (and should)
provide a comprehensive pharmaceutical service. This is evidenced, for
example, by the International Pharmaceutical Federation's ‘Good
Pharmacy Practice (GPP) in developing countries’ guide [20]. Further
illustrations of this shift include Indonesia's ‘Pharmaceutical Services
Guidelines’ in ‘apoteks’ (pharmacies) [21] and the Pharmacy Council of
India's 2015 ‘Pharmacy Practice Regulations’. The latter clearly lays out
a code of ethics, and the duties and responsibilities of a pharmacist
(which include promoting rational drug use, patient counselling,
management of minor ailments, and public health duties) [22].
While the empirical literature on quality of TB care from pharmacies
in LMICs is relatively sparse, the quality challenges are clearly evident,
relating to anti-TB medicine availability, quality of anti-TB medicines,
and pharmacy worker's knowledge. Further, management practices
suﬀer from a lack of questioning of symptomatic patients to ascertain
whether they require testing, lack of referral of TB suspects, sale of
unnecessary and harmful medicines, sale of anti-TB medication OTC,
and lack of counselling. These ﬁndings are very much in keeping with
the shortfalls in pharmacy practice identiﬁed for other diseases [11,12].
Given that it is 13 years since the WHO actively encouraged coun-
tries to engage pharmacists and drug shops into national TB pro-
grammes [8], the number of published interventions in this area is
strikingly few (we acknowledge that there are a number of interven-
tions lacking published ﬁndings). Of the interventions scrutinised by
this paper (Table 3), participants found the interventions to be accep-
table and many reported professional satisfaction from their involve-
ment. Whilst active participation in these programmes appears to have
been low, with the right set of incentives and support, high participa-
tion levels have been achieved and in one study case-detection through
pharmacies was shown to be cost-eﬀective [58].
All these interventions have explicitly focussed on engaging phar-
macies in the national TB programme to improve case detection. Whilst
appropriate referrals and hence improved case detection represents an
important aspect of quality, the narrative of these papers appears to
lack discussion of other dimensions of quality of care. It is clear that,
thus far, a focus on quality has been a ‘missing ingredient’ in eﬀorts to
harness pharmacies to improve TB control [13]. Future interventions
would do well to tackle the seemingly neglected areas of OTC pre-
scribing of unnecessary and harmful medicines, and measures to im-
prove patient counselling to accompany the sale of anti-TB medicines.
The implemented interventions have generally shown a reasonable
degree of success but achieving scale remains a challenge, a challenge
also identiﬁed with engagement of other for-proﬁt providers [64]. An
analysis of the problems in engaging private providers more broadly
highlighted a number of barriers to reaching scale in PPM programmes.
These include, amongst others, a bias towards public provision, lack of
funding, a lack of understanding of private healthcare markets, high
level of fragmentation in these markets, market incentives favouring
poor quality care, and competing priorities [6]. Building a strong evi-
dence base, advocating for enhanced political commitment and
funding, utilisation of digital technology, setting ambitious PPM tar-
gets, and monitoring the progress of PPM initiatives may help to
overcome some of these obstacles [64].
It was noticeable that none of the interventions included a reg-
ulatory component, although regulatory systems exist with mandates
for pharmacy in all countries. Lack of regulatory oversight is a clear
problem in the pharmacy retail sector in many LMICs and an area that
warrants attention (both generally and in relation to TB care).
Regulatory interventions have shown promising improvements in
pharmacy service quality in the past [65,66]. Whilst studies reported
that sales of anti-TB medicines OTC were commonplace in some
countries e.g., Vietnam [32]; in other countries, such as India, this was
reported to be rare (despite being very common other antibiotics) (e.g.,
[30,55]). A detailed examination of regulatory policies surrounding
anti-TB medicine may provide useful cross-country learning
experiences. For example, other countries could explore the possibility
of initiating hierarchies of drug control in the way that India has in-
stigated the H1 drug schedule which includes more restrictions and
stricter penalties for selling anti-TB medicines in a bid to halt the
emergence of resistant antibiotic strains.
This paper has also highlighted the lack of explicit global-level
guidelines aimed at pharmacies, outlining how they should manage TB
patients. This has similarly been emphasised as a major gap for the
management of other conditions that present at the pharmacy, such as
childhood diarrhoea [40]. A concise handbook aimed at LMIC phar-
macies outlining the key management ‘dos and don'ts’ for conditions of
high public health importance would be a key contribution from the
global health community. Such an endeavour could draw on guidelines
previously produced by local pharmacy associations (e.g., the India
Pharmaceutical Association's guidance on TB management [28]). A key
ﬁrst step would be the identiﬁcation of all such existing guidance for a
range of conditions (which is often not publicly available or only
available in a local language). Organisations such as FIP and the WHO
(speciﬁcally the Department of Essential Medicines and Health Pro-
ducts), which have a strong presence and legitimacy in the global
pharmacy space, would be well-placed to spearhead such an initiative.
Appropriate training should also be incorporated into pharmacy pre-
service education. Additionally, the role of non-pharmacist run phar-
macies and drug shops requires clariﬁcation.
Looking forward, technological innovations could further extend
the role of pharmacies in TB care. Glaze and Rowe have suggested that
pharmacists in the US are well placed to administer a puriﬁed protein
derivative skin test, read the results, and provide education to the pa-
tient [67]. Moulding proposes that private doctors in LMICs could
prescribe ‘monitored self-administered treatment’, whereby pharmacies
would ﬁll and dispense medication monitors (as opposed to anti-TB
medication either loose or in its original packaging) in order to improve
adherence in the private sector [68].
While many approaches are possible, the current reality of phar-
macy care for TB patients remains substandard. Given the importance
of pharmacies in LMICs as an early point of contact for TB patients,
there remains a critical agenda of work to ensure the potential beneﬁts
for TB control can be maximised. Addressing quality of care at the
pharmacy level, will require the participation and collaboration of a
wide range of stakeholders, going well beyond the pharmacies them-
selves. This complex landscape involves organisations at the global
level, such as WHO, FIP, and the STOP TB programme; and at the
country level, national TB programmes, regulatory bodies, pharmacy
associations, pharmacy colleges and ministries of health. Given that in
the TB context, community pharmacy sits at the intersection between
policies for TB and policies that focus on pharmacy more generally,
these two groups of stakeholders will need to come together to eﬀect
change.
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